©
Biotech TV
They talked about how Infinitopes developed from a spin-out into a clinical stage company recruiting its first clinical trial, as well as its strategy of layering investors from Kindred Capital VC to Octopus Ventures to Amplify Partners in the US.
As part of the discussion, NED Dr Jo Brewer provided some further insight into the company’s precision immunomics approach.
The BioEscalator looks great in the footage! This was BiotechTV’s second visit here, and we hope to welcome it back again soon.
Biotech TV also talked to Professors Matthew Wood and Carlo Rinaldi at the Oxford-Harrington Rare Disease Centre about research into diseases such as Friedreich’s ataxia and grant funding for translation. Both have close links to the BioEscalator – serial entrepreneur Professor Wood is a co-founder of tenants ISOgenix and Orfonyx Bio, plus Chair of our Management Board. Professor Rinaldi is also a co-founder of ISOgenix.
You can enjoy the interviews on Biotech TV.